Company / Operating Income
Acadia Pharmaceuticals Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$104.8M
FY2025
5-year range
-$223.6M / $230.8M
FY2021-FY2025
Trend
-54.6%
vs FY2024
Sector context
#37 of 204
Health Care
What the data says
Acadia Pharmaceuticals's operating income of $105M is higher than 82% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from -$292M in FY2017 to $231M in FY2024.
Based on SEC 10-K filings.
$105M in FY2025. Top quartile in the Health Care sector.
Improved from -$73M to $105M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 204This company $104.8M Sector average $107.8M
▼
-2.7% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 54.6% year-over-year.
- Ranks #37 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $104.8M | -54.6% |
| FY2024 | $230.8M | +414.5% |
| FY2023 | -$73.4M | +67.2% |
| FY2022 | -$223.6M | -31.2% |
| FY2021 | -$170.4M | +40.5% |
| FY2020 | -$286.6M | -16.2% |
| FY2019 | -$246.5M | +0.4% |
| FY2018 | -$247.4M | +15.4% |
| FY2017 | -$292.4M | -7.2% |
| FY2016 | -$272.8M | -65.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026